REG - Haleon PLC - Proposed off-market purchase alongside Pfizer

HALEONAnnouncement

18/03/2025 17:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250318:nRSR1787Ba&default-theme=true

RNS Number : 1787B  Haleon PLC  18 March 2025

 

Haleon plc: Proposed off-market purchase alongside Pfizer Inc. offering

 

18 March 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) notes
the announcement today by Pfizer Inc. ("Pfizer") of its proposed offering of
ordinary shares of £0.01 each in the Company to institutional investors by
way of an accelerated bookbuild offering process (the "Proposed Offering").

 

Haleon has agreed with Pfizer to make an off-market purchase of approximately
£170 million worth of ordinary shares from Pfizer, subject to (a) the
offering price per ordinary share in the Proposed Offering (the "Share
Offering Price") being no more than the price per ordinary share as at close
of trading today on the main market of the London Stock Exchange, and (b)
completion of the Proposed Offering.

 

Subject to completion of the off-market purchase, the purchase price per
ordinary share to be paid by Haleon to Pfizer will be equal to the Share
Offering Price.

 

The off-market purchase will represent a portion of the £500 million
allocated to share buybacks in 2025 announced on 27 February 2025. Haleon
intends to cancel the purchased ordinary shares.

 

Further details will be provided following announcement by Pfizer of the
results of the Proposed Offering.

 

Amanda Mellor

Company Secretary

 

 

Enquiries

 

 Investors                                    Media

 Jo Russell              +44 7787 392441      Zoë Bird            +44 7736 746167
 Rakesh Patel            +44 7552 484646      Victoria Durman     +44 7894 505730
 Emma White              +44 7823 523562

 Email: investor-relations@haleon.com         Email: corporate.media@haleon.com

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans five major categories - Oral Health, Pain Relief, Respiratory Health,
Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu,
Otrivin, Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.

 

For more information please visit www.haleon.com (http://www.haleon.com)

 

 

Not for release, publication or distribution in the United States, Canada,
Japan, Australia or any other state or jurisdiction in which such release,
publication or distribution would be unlawful.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCQVLFFEXLZBBV